QT Interval Effects and M-Protein Response in a Phase 1 Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

被引：0

作者：

Thomas, Sheeba K. ^{[1
]}

Suvorov, Alexander ^{[2
]}

Noens, Lucien ^{[3
]}

Rukavitsin, Oleg ^{[4
]}

Fay, Joseph ^{[5
]}

Wu, Ka Lung ^{[6
]}

Zimmerman, Todd M. ^{[7
]}

van de Velde, Helgi ^{[8
]}

Bandekar, Rajesh ^{[9
]}

Puchalski, Thomas A. ^{[10
]}

Qi, Ming ^{[11
]}

Uhlar, Clarissa ^{[11
]}

Samoilova, Olga S. ^{[12
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[2] First Republican Clin Hosp Udmurtia, Izhevsk, Russia

[3] Ghent Univ Hosp, Ghent, Belgium

[4] Main Mil Clin Hosp, Moscow, Russia

[5] Baylor Univ, Sammons Canc Ctr, Dallas, TX USA

[6] ZNA Stuivenberg, Hematol, Antwerp, Belgium

[7] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[8] Janssen Res & Dev LLC, Oncol, Beerse, Belgium

[9] Janssen Res & Dev LLC, Biostat Oncol, Spring House, PA USA

[10] Janssen Res & Dev LLC, Biol Clin Pharmacol, Biotechnol Ctr Excellence, Spring House, PA USA

[11] Janssen Res & Dev LLC, Hematol & Oncol Gen, Spring House, PA USA

[12] Reg Clin Hosp Na Semashko, Nizhnii Novgorod, Russia

来源：

关键词：

D O I：

10.1182/blood.V120.21.2972.2972

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2972

引用

页数：2